


Figure 1A




Figure 1B




Figure 1C




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 4A



Control
-FGF2 D7
Addition of FGF2 to -FGF2 D7
-FGF2 D14
Addition of FGF2 to -FGF2 D14
counts
mAb 375

Figure 4B




Figure 5A




Figure 5B



100
80
60
40
20
0
Relative Viability (%)
24
72
120
Time (hours)
0.2% DMSO
100μM peptide

Figure 5C



0.2% DMSO
100uM peptide
Viable cell number (10^5)
Time (hours)
counts
mAb 375

Figure 6




Figure 7A




Figure 7B



Relative mean fluorescence level
4
3
2
1
0
*
0.2% DMSO
100μM peptide

Figure 7C



iPS
Tra1-60
mAb 375
mAb 529
counts
FL1
0
20
40
60
80
100
10^0
10^1
10^2
10^3

Figure 8A



iPS EB
Tra1-60
mAb 375
mAb 529
counts
FL1
0
20
40
60
80
100
10^0
10^1
10^2
10^3

Figure 8B




Figure 9




Figure 10




Figure 11A




Figure 11B



Population expressing caspase-3 activity (%)
80
70
60
50
40
30
20
10
0
*
0.2% DMSO
100μM peptide

Figure 11C



Relative viability (%)
100
80
60
40
20
0
0
20
40
60
80
100
120
140
160
180
200
Concentration (μM)

Figure 12



Relative viability (%)
100
80
60
40
20
0
DMSO
D(KLAKLAK)2
100μM L-form apoptotic peptide
200μM L-form apoptotic peptide
100μM D-form apoptotic peptide

Figure 13